Background: The clinical relevance of serum glial fibrillary acidic protein (sGFAP)
concentration as a biomarker of MS disability progression independent of acute …

Importance There is a lack of validated biomarkers for disability progression independent of
relapse activity (PIRA) in multiple sclerosis (MS). Objective To determine how serum glial …

Background and Objectives Neurodegeneration and astrocytic activation are pathologic
hallmarks of progressive multiple sclerosis (MS) and can be quantified by serum …

Background: Predicting disability worsening in multiple sclerosis (MS) remains an important
challenge. Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) seem …

Objective Insidious disability worsening is a common feature in relapsing–remitting multiple
sclerosis (RRMS). Many patients experience progression independent of relapse activity …

Background: Cerebrospinal fluid (CSF) levels of two soluble biomarkers, glial fibrillary acidic
protein (GFAP) and neurofilament light chain (NfL), have been shown to associate with …

Background: Cognitive decline is inadequately captured by the standard neurological
examination. Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein …

Objective Progression prediction is a significant unmet need in people with progressive
multiple sclerosis (pwPMS). Studies on glial fibrillary acidic protein (GFAP) have either been …

The major intermediate cytoskeletal protein of astrocytes, glial fibrillary acidic protein
(GFAP), and that of axons, neurofilament light protein (NFL), may both be released into the …

Importance Biomarkers distinguishing nonrelapsing progressive disease biology from
relapsing biology in multiple sclerosis (MS) are lacking. Cerebrospinal fluid (CSF) is an …